DS-7250 -Evaluation of Safety, Pharmacokinetics, and Pharmacodynamics After Multiple Oral Administration in Patients With Type 2 Diabetes-
Latest Information Update: 26 May 2016
At a glance
- Drugs DS 7250 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 26 May 2016 New trial record